• Explore /
  • Poster
  • / Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for high risk, clinically localized prostate cancer: ENZARAD (ANZUP 1303).

Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for high risk, clinically localized prostate cancer: ENZARAD (ANZUP 1303).

Abstract Poster

Authors

null

Scott Williams

Peter MacCallum Cancer Centre, Melbourne, Australia

Scott Williams , Ian D. Davis , Christopher Sweeney , Martin R. Stockler , Andrew James Martin , Wendy Hague , Xanthi Coskinas , Sonia Yip , Emily Tu , Nicola Jane Lawrence , Namrata Nayar , Ray McDermott , Paul Kelly , Olwyn Deignan , Simon Hughes , Valerie Fonteyne , Bertrand F. Tombal , Paul L. Nguyen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Prostate Cancer

Track

Prostate Cancer,Prostate Cancer

Sub Track

Prostate Cancer - Localized Disease

Clinical Trial Registration Number

NCT02446444

Citation

J Clin Oncol 36, 2018 (suppl 6S; abstr TPS156)

DOI

10.1200/JCO.2018.36.6_suppl.TPS156

Abstract #

TPS156

Poster Bd #

N19

Abstract Disclosures

Similar Posters

First Author: Scott Williams

First Author: Scott G. Williams

First Author: Scott G. Williams

First Author: Junlong Zhuang